Advertisement

Amendment history:

Research Article Free access | 10.1172/JCI112233

Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy.

P S Creticos, N F Adkinson Jr, A Kagey-Sobotka, D Proud, H L Meier, R M Naclerio, L M Lichtenstein, and P S Norman

Find articles by Creticos, P. in: JCI | PubMed | Google Scholar

Find articles by Adkinson, N. in: JCI | PubMed | Google Scholar

Find articles by Kagey-Sobotka, A. in: JCI | PubMed | Google Scholar

Find articles by Proud, D. in: JCI | PubMed | Google Scholar

Find articles by Meier, H. in: JCI | PubMed | Google Scholar

Find articles by Naclerio, R. in: JCI | PubMed | Google Scholar

Find articles by Lichtenstein, L. in: JCI | PubMed | Google Scholar

Find articles by Norman, P. in: JCI | PubMed | Google Scholar

Published December 1, 1985 - More info

Published in Volume 76, Issue 6 on December 1, 1985
J Clin Invest. 1985;76(6):2247–2253. https://doi.org/10.1172/JCI112233.
© 1985 The American Society for Clinical Investigation
Published December 1, 1985 - Version history
View PDF
Abstract

Challenge of the nasal mucosa of allergic subjects with specific allergen induces not only the expected sneezing and rhinorrhea, but also the appearance in nasal secretions of mediators commonly associated with activation of mast cells or basophils: histamine, leukotrienes, prostaglandin D2 (PGD2), kinins, and TAME ([3H]-N-alpha-tosyl-L-arginine methyl ester)-esterase. To determine whether specific immunotherapy alters mediator release in vivo, nasal pollen challenge was used to compare 27 untreated highly sensitive ragweed (RW)-allergic subjects with 12 similarly sensitive patients receiving long-term immunotherapy (3-5 yr) with RW extract (median dose, 6 micrograms RW antigen E). The two groups were equally sensitive based on skin tests and basophil histamine release. The immunized group had a diminished response as demonstrated by (a) the treated group required higher pollen doses to excite sneezing or mediator release; (b) significantly fewer subjects in the treated group released mediators at any dose (TAME-esterase [P = 0.005], PGD2 [P = 0.04]), and (c) the treated group released 3-5-fold less mediator (TAME-esterase [P = 0.01], and histamine [P = 0.02]).

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (December 1, 1985): No description
Advertisement
Advertisement